AMRX vs. LLY
Compare and contrast key facts about Amneal Pharmaceuticals, Inc. (AMRX) and Eli Lilly and Company (LLY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: AMRX or LLY.
Correlation
The correlation between AMRX and LLY is 0.46, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
AMRX vs. LLY - Performance Comparison
Key characteristics
AMRX:
0.37
LLY:
-0.06
AMRX:
0.78
LLY:
0.21
AMRX:
1.09
LLY:
1.03
AMRX:
0.14
LLY:
-0.05
AMRX:
1.24
LLY:
-0.11
AMRX:
9.84%
LLY:
12.37%
AMRX:
36.05%
LLY:
37.94%
AMRX:
-97.52%
LLY:
-68.27%
AMRX:
-85.46%
LLY:
-21.46%
Fundamentals
AMRX:
$3.51B
LLY:
$737.66B
AMRX:
-$0.04
LLY:
$12.27
AMRX:
1.24
LLY:
15.05
AMRX:
86.10
LLY:
46.91
AMRX:
$2.83B
LLY:
$49.00B
AMRX:
$1.04B
LLY:
$40.03B
AMRX:
$511.54M
LLY:
$16.67B
Returns By Period
In the year-to-date period, AMRX achieves a -5.81% return, which is significantly lower than LLY's -2.49% return. Over the past 10 years, AMRX has underperformed LLY with an annualized return of -16.69%, while LLY has yielded a comparatively higher 28.61% annualized return.
AMRX
-5.81%
6.72%
-13.36%
13.20%
16.07%
-16.69%
LLY
-2.49%
3.47%
-5.45%
-2.41%
39.23%
28.61%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
AMRX vs. LLY — Risk-Adjusted Performance Rank
AMRX
LLY
AMRX vs. LLY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Amneal Pharmaceuticals, Inc. (AMRX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
AMRX vs. LLY - Dividend Comparison
AMRX has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.72%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AMRX Amneal Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.72% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% | 2.84% |
Drawdowns
AMRX vs. LLY - Drawdown Comparison
The maximum AMRX drawdown since its inception was -97.52%, which is greater than LLY's maximum drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for AMRX and LLY. For additional features, visit the drawdowns tool.
Volatility
AMRX vs. LLY - Volatility Comparison
The current volatility for Amneal Pharmaceuticals, Inc. (AMRX) is 14.23%, while Eli Lilly and Company (LLY) has a volatility of 22.38%. This indicates that AMRX experiences smaller price fluctuations and is considered to be less risky than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
AMRX vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Amneal Pharmaceuticals, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AMRX vs. LLY - Profitability Comparison
AMRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Amneal Pharmaceuticals, Inc. reported a gross profit of 255.89M and revenue of 695.42M. Therefore, the gross margin over that period was 36.8%.
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported a gross profit of 10.50B and revenue of 12.73B. Therefore, the gross margin over that period was 82.5%.
AMRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Amneal Pharmaceuticals, Inc. reported an operating income of 100.35M and revenue of 695.42M, resulting in an operating margin of 14.4%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported an operating income of 5.41B and revenue of 12.73B, resulting in an operating margin of 42.5%.
AMRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Amneal Pharmaceuticals, Inc. reported a net income of 24.62M and revenue of 695.42M, resulting in a net margin of 3.5%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported a net income of 2.76B and revenue of 12.73B, resulting in a net margin of 21.7%.